- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | XFRA EKW0: AUSSETZUNG/SUSPENSION | 89 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPSYENCE GROUP INC.... ► Artikel lesen | |
| PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 25.11. | Psyence Group Inc (2): Psyence enters definitive merger deal with GoldCoast | 2 | Stockwatch | ||
| 24.11. | Psyence Group Inc (2): Psyence Group to remain halted | 1 | Stockwatch | ||
| 24.11. | CSE Bulletin: Halted for Fundamental Change - Psyence Group Inc. (PSYG) | 214 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - Trading in the shares of Psyence Group Inc. (PSYG) will remain halted pending receipt and review of acceptable documentation regarding... ► Artikel lesen | |
| 24.11. | Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp. | 417 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 24, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company") is pleased to announce that, further to its news release dated August 22, 2025, it has... ► Artikel lesen | |
| 18.10. | Psyence Group Inc (2): Psyence Group grants 721,448 RSUs | 1 | Stockwatch | ||
| 17.10. | Psyence Group Inc. Announces RSU Grants | 412 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / October 17, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU")... ► Artikel lesen | |
| 22.08. | Psyence Group Inc (2): Psyence Group enters LOI to acquire GoldCoast | 3 | Stockwatch | ||
| 22.08. | XFRA EKW0: WIEDERAUFNAHME/RESUMPTION | 409 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 22.08. | Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp. | 428 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the... ► Artikel lesen | |
| 08.07. | Psyence Group Inc (2): Psyence closes $124,000 second tranche of placement | 1 | Stockwatch | ||
| 07.07. | Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds | 449 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of... ► Artikel lesen | |
| 26.06. | Psyence Group Inc (2): Psyence closes $476,000 first tranche of financing | 1 | Stockwatch | ||
| 25.06. | PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares | 1 | GlobeNewswire (USA) | ||
| 23.04. | XFRA 8VC0,BC21,EKW0,1S90: AUSSETZUNG/SUSPENSION | 242 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGREAT PLAINS MET.... ► Artikel lesen | |
| 23.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.04.2025 | 462 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.04.2025
Aktien
1 US7866231084 AB Sagax ADR
2 US36170Y1038... ► Artikel lesen | |
| 22.04. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.04.2025 | 526 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.04.2025ISIN NameCA00833F3079 AFRICAN... ► Artikel lesen | |
| 22.04. | XFRA ISIN CHANGE | 550 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA00833F3079 African Energy Metals Inc. 22.04.2025 CA5589221004 Magma Silver Corp. 23.04.2025 Tausch 1:1CA74449Q1063 Psyence... ► Artikel lesen | |
| 22.04. | CSE Bulletin: Consolidation - Psyence Group Inc. (PSYG) | 416 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 21 avril/April 2025) - Psyence Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated... ► Artikel lesen | |
| 17.04. | Psyence Group Inc.: Psyence Group Announces Share Consolidation | 231 | GlobeNewswire (Europe) | TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDGEWISE THERAPEUTICS | 22,730 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,68 | -4,81 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,300 | -1,85 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 71,97 | +0,15 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| IMMUNOME | 23,390 | 0,00 % | Immunome prices public offering of common stock at $21.50 per share | ||
| OLEMA PHARMACEUTICALS | 34,250 | -4,41 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 36,010 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,170 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VOR BIOPHARMA | 15,850 | 0,00 % | Vor Bio raises $150 million in private placement to fund clinical trials | ||
| ARCELLX | 66,24 | -3,07 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| PRAXIS PRECISION MEDICINES | 274,78 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 15,355 | 0,00 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,960 | -0,70 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 18,640 | +13,31 % | Why Is Monte Rosa Stock Trading Higher Today? | ||
| KYMERA THERAPEUTICS | 84,12 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen |
Das Unternehmen PSYENCE GROUP INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,064 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE GROUP INC finden Sie auf Wallstreet Online.